Elafibranor

Cat. No.: 0225LY-0834

Appearance: Solid

Purity: ≥98%

Identity: Confirmed by NMR, HPLC, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Elafibranor acts as an agonist for both PPAR-alpha (EC50: 45 nM) and PPAR-delta (EC50: 175 nM).

Synonym: GFT505; 923978-27-2; GFT-505; Elafibranor(GFT505); (E/Z)-Elafibranor; GFT 505; 2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid; (E)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid; 2-{2,6-dimethyl-4-[(1E)-3-[4-(methylsulfanyl)phenyl]-3-oxoprop-1-en-1-yl]phenoxy}-2-methylpropanoic acid; 2-(2,6-Dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid; 2-[2,6-dimethyl-4-[(~{E})-3-(4-methylsulfanylphenyl)-3-oxidanylidene-prop-1-enyl]phenoxy]-2-methyl-propanoic acid; Propanoic acid, 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propen-1-yl)phenoxy)-2-methyl-

CAS No.: 923978-27-2

Compound CID: 9864881

Formula: C₂₂H₂₄O₄S

Formula Weight: 384.49

Specification

Targets&IC50: PPARα: 45 nM (EC50); PPARδ: 175 nM (EC50)

Relative Density: 1.21 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Elafibranor can be used in hepatology research to examine the dual agonism of PPAR alpha and delta in the context of non-alcoholic steatohepatitis (NASH).